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Abstract
Background: A key procedure of the rhythm control strategy in atrial fibrillation (AF) is 
cardioversion to normal sinus rhythm. The aim of the present study was to provide a review 
of treatment patterns for the cardioversion of patients with AF in a hospital setting in Poland 
and document the success rate of various cardioversion procedures.
Methods: We herein present the results from Poland of a prospective observational study to 
characterize patients with recent onset episodes of AF for whom cardioversion is one of the 
planned therapeutic options — the RHYTHM-AF registry. Consecutive patients in the hospital 
setting, age > 18 years, with documented AF at the time of enrollment, excluding those with 
atrial flutter and those treated with vernakalant, were recruited. No treatment was recommen-
ded nor discouraged.
Results: Five hundred and one patients were recruited (mean age 64.2 ± 12.1), with 294 
(58.7%) patients finally undergoing cardioversion. Primary electrical cardioversion (ECV) 
was successful in 131 (88.5%) patients. Primary pharmacological cardioversion (PCV) was 
successful in 110 (75.3%) patients. Amiodarone and propafenone were most commonly used 
(52.1% and 24.7%, respectively). Fourteen complications and adverse events were recorded (no 
stroke was observed).
Conclusions: Conversion to sinus rhythm was attempted in < 60% of the patients with AF 
admitted to the hospital with an intention to terminate arrhythmia. ECV was successful in 
~90% of the patients, while PCV in ~75% of the patients (amiodarone and propafenone 
were most commonly used). The rate of complications was low (2.8%). (Cardiol J 2014; 21, 5: 
484–491)
Key words: atrial fibrillation, electrical cardioversion, pharmacological  
cardioversion, registry
ORIGINAL ARTICLE
Cardiology Journal 
2014, Vol. 21, No. 5, pp. 484–491
DOI: 10.5603/CJ.201CJ.a2014.0018
Copyright © 2014 Via Medica
ISSN 1897–5593
484 www.cardiologyjournal.org
Address for correspondence: Marek Kiliszek, MD, PhD, 1st Chair and Department of Cardiology, Medical University  
of Warsaw, ul. Banacha 1a, 02–097 Warszawa, Poland, tel: +48 22 599 29 58, fax: +48 22 599 19 57, e-mail: kiliszek@mp.pl
Received: 24.09.2013 Accepted: 21.01.2014
Introduction
Atrial fibrillation (AF) is the most common 
arrhythmia observed in clinical practice, with 
prevalence increasing with age. It has been esti-
mated that over 6 million people in the European 
Union have AF and the number has doubled during 
the last 50 years due to aging of the population [1]. 
AF increases mortality and the risk of stroke and 
decreases quality of life [2].
Two strategies of AF treatment can be applied: 
rhythm control or rate control [1]. A key procedure 
in the rhythm control strategy is cardioversion to 
sinus rhythm (SR), which can be achieved through 
pharmacologic or electrical means. Electrical car-
dioversion (ECV) is proven more effective than 
pharmacological cardioversion (PCV) [3], but it is 
costly, requires presence of an anesthesiologist and 
can be time-consuming.
The aim of the present manuscript is to pro-
vide a review of treatment patterns for the cardio-
version of patients with recent-onset AF in hospital 
setting in Poland and document the success rate of 
various cardioversion procedures.
Methods
Study design
RHYTHM-AF was a prospective observational 
study conducted in 10 countries: Australia, Brazil, 
France, Germany, Italy, the Netherlands, Poland, 
Spain, Sweden, and the United Kingdom. Patients 
with recent-onset of AF considered for cardiover-
sion were enrolled from participating hospitals and 
acute care centers between May 2010 and June 
2011 [4]. In this manuscript, only results from 
Poland will be presented.
Study population
Centers recruiting patients were selected as 
representatives of this way of treating AF in the 
participating countries. All patients considered 
for the study were at least 18 years old with docu-
mented AF, confirmed by electrocardiogram and 
cardioversion was one of the planned therapeutic 
options. All patients signed an informed consent. 
Only patients who were already enrolled in the 
current trial, otherwise enrolled in a separate trial, 
and patients with atrial flutter were excluded.
PCV was considered successful if SR or atrial 
rhythm was obtained within 24 h following the ini-
tiation. Time to SR was, however, noted separately. 
ECV was defined as successful if SR was obtained 
and maintained for at least 10 min following the 
last shock.
All patient data were collected via a remote 
web based data collection form using the multi-
lingual software solution EBogen©, developed by 
the IHF Ludwigshafen, Germany (the coordinating 
center for the study).
Statistical analyses
All data are presented as mean ± standard 
deviation, median and interquartile (IQR) range or 
number and percent of population, depending on 
characteristic of the parameter. All comparisons 
were made using c2 or Kruskal-Wallis tests.
Results
In Poland, 501 patients in 15 centers were 
included into the analyses. Major characteristics of 
the study group are shown in Table 1. Two hundred 
and ninety four patients underwent cardioversion 
(148 — primary ECV, 146 — primary PCV), while 
in 207 patients no cardioversion was attempted. 
In almost half of these patients (n = 92, 44.4%), 
cardioversion was planned following the dischar-
ge, in 26.6% (55 patients) there was spontaneous 
conversion to SR. Flow of the patients and detailed 
reasons for not attempting to cardioversion are 
shown in Figure 1.
Comparison between primary ECV  
and primary PCV patients
Clinical characteristic of patients who prima-
rily underwent ECV included younger aged and 
less frequently women than those cardioverted 
pharmacologically. The distribution of concomitant 
diseases (hypertension, diabetes, coronary artery 
disease) was comparable between the ECV and 
PCV groups (and so was CHADS2 and CHA2DS2- 
-VASc score) with the exception of heart failure 
and valvular heart disease — these patients more 
frequently underwent ECV. Major differences 
between ECV and PCV patients were AF charac-
teristics: among patients who underwent ECV, 
paroxysmal AF was less frequent, persistent AF 
was more common, and the duration of the longest 
previous episode was different (91.3 vs. 0.8 days), 
as was the duration of the current episode (57.0 
vs. 0.0 days).
Electrical cardioversion
One hundred and forty eight patients unde-
rwent primary ECV (50.3% of patients who unde-
rwent any cardioversion). The primary reason for 
admission among the vast majority of patients was 
AF (92.6%). Median time to cardioversion among 
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those who underwent primary ECV was 24:29 h 
(IQR 6:21–42:13). A median of total length of 
hospital stay was 54:19 h (IQR 47:36–92:14) (no 
significant differences between groups with suc-
cessful or unsuccessful ECV). Cardioversion was 
successful among those who underwent primary 
ECV in 131 (88.5%) patients. For 1 patient, treat-
ment was changed from ECV to PCV.
Figure 1. Patient flow in the Polish subset of RHYTHM-AF registry; *Choosing more than one option was available; 
AF — atrial fibrillation; ECV — electrical cardioversion; PCV — pharmacological cardioversion; SR — sinus rhythm.
Table 1. Major characteristic of the registry group (percentages and numbers or medians and quartiles 
or mean and standard deviation are given).
Demographics  
and risk factors
Total  
(n = 501)
Primary ECV group  
(n = 148)
Primary PCV group  
(n = 146)
P*
Age 64.2 ± 12.1 61.6 ± 11.7 66.8 ± 12.7 0.0003
Women 193 (38.7%) 40 (26.8%) 72 (49.3%) 0.0001
Body mass index 29.1 ± 4.6 29.3 ± 4.7 28.6 ± 4.5 0.19
Hypertension 375 (75.0%) 108 (73%) 121 (82.9%) 0.056
Diabetes 104 (20.8%) 31 (20.8) 30 (20.5%) 0.95
Hyperlipidemia 238 (52.3%) 79 (55.6%) 75 (60.5%) 0.82
CAD 124 (24.8%) 36 (24.2%) 36 (24.7%) 0.95
Previous MI 80 (16.0%) 25 (16.8%) 21 (14.4%) 0.66
Heart failure 120 (24.0%) 49 (32.9%) 21 (14.4%) 0.0003
Valvular heart disease 90 (18.5%) 36 (24.2%) 13 (9.6%) 0.0007
CHADS2 score 1.5 ± 1.0 1.5 ± 0.9 1.6 ± 1.0 0.37
CHA2DS2-VASc score 2.7 ± 1.7 2.5 ± 1.6 2.9 ± 1.6 0.038
AF characteristic
First detected episode of AF 88 (17.6%) 11 (7.4%) 44 (30.1%) < 0.0001
Paroxysmal AF 191 (38.1%) 27 (18.1%) 89 (61.0%) < 0.0001
Persistent AF 204 (40.7%) 105 (70.5%) 11 (7.5%) < 0.0001
Chronic AF 11 (2.2%) 3 (2.0%) 1 (0.7%) 0.62
Number of previous  
symptomatic episodes
2 (1–10) 2 (1–6) 5 (1–15) 0.01
Duration of longest  
previous episode** 
4 (0.8–91.3) 91.3 (42–274) 0.8 (0.2–2.0) < 0.0001
Duration of current  
episode of AF** 
1.0 (0.0–58.0) 57.0 (2.0–167.5) 0.0 (0.0–1.0) < 0.0001
Time since first episode  
of AF ever** 
1201.5  
(269.0–3551.0)
889.5  
(239.0–3241.0)
1302.0  
(263.0–3677.5)
0.30
*For the differences between primary ECV and primary PCV groups; **days; AF — atrial fibrillation; CAD — coronary artery disease;  
ECV — electrical cardioversion; MI — myocardial infarction; PCV — pharmacological cardioversion
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The total number of patients who underwent 
external ECV (including those converted from 
PCV) was 165 (98.2%). Mean energy of the first 
shock was 157.7 ± 47.2, with no differences be-
tween successful and unsuccessful cardioversion. 
One ECV was done transesophageally (but was 
unsuccessful), and two were made from implan-
table cardioverter-defibrillator (both successful). 
An anesthesiologist was present in 135 (81.8%) 
cases of all ECVs. SR was eventually obtained in 
148 patients among those receiving ECV.
Comparing patients with successful and unsuc-
cessful primary ECV, the only parameter lower in 
patients with successful primary ECV was the num-
ber of previous symptomatic episodes (Table 2). 
All patients except for one were discharged from 
hospital. One hundred and fourteen (86.4%) pa-
tients with a successful first ECV and 3 (17.6%, 
p < 0.0001) with an unsuccessful ECV were in SR 
at discharge.
Pharmacological cardioversion
One hundred and forty six (49.7%) patients 
primarily underwent PCV. The primary reason for 
admission was AF in 121 (82.9%) patients. Other 
reasons for admission included acute coronary 
Table 2. Factors correlated with successful primary electrical cardioversion (ECV) and primary pharma-
cological cardioversion (PCV).
Demographics  
and risk factors
Primary ECV  
successful  
(n = 131)
Primary ECV  
not successful  
(n = 17)
P Primary PCV  
successful  
(n = 110)
Primary PCV  
not successful  
(n = 36)
P
Age 61.6 ± 11.8 61.6 ± 11.6 0.96 66.7 ± 13.1 67.1 ± 11.7 0.98
Women 33 (25.0%) 7 (41.2%) 0.16 58 (52.7%) 14 (38.9%) 0.15
Body mass index 29.1±4.8 30.8±3.6 0.07 28.9 ± 4.5 27.8 ± 4.1 0.19
Hypertension 95 (72.5%) 13 (76.5%) 0.73 93 (84.5%) 28 (77.8%) 0.35
Diabetes 25 (18.9%) 6 (35.3) 0.12 26 (23.6%) 4 (11.1) 0.11
Hyperlipidemia 70 (55.1%) 9 (60.0%) 0.72 57 (61.3%) 18 (58.1%) 0.75
CAD 30 (22.7%) 6 (35.3%) 0.25 27 (24.5%) 9 (25.0%) 0.96
Previous MI 22 (16.7%) 3 (17.6%) 0.92 16 (14.5%) 5 (13.9%) 0.92
Heart failure 43 (32.6%) 6 (35.3%) 0.82 13 (11.8%) 8 (22.2%) 0.12
Valvular heart disease 29 (22.0%) 7 (41.2%) 0.08 10 (9.3%) 3 (10.3%) 0.87
CHADS2 score 1.4 ± 0.9 1.6 ± 1.0 0.34 1.6 ± 1.1 1.5 ± 0.8 0.59
CHA2DS2-VASc score 2.4 ± 1.5 2.8±1.7 0.52 3.0 ± 1.7 2.7 ± 1.5 0.33
AF characteristic
First detected  
episode of AF
11 (8.3%) 0 (0.0%) 0.22 39 (35.5%) 5 (13.9%) < 0.05
Paroxysmal AF 24 (18.2%) 3 (17.6%) 0.98 64 (58.2%) 25 (69.4%) 0.23
Persistent AF 91 (68.9%) 14 (82.4%) 0.25 6 (5.5%) 5 (13.9%) 0.10
Chronic AF 3 (2.3%) 0 (0.0%) 0.53 0 (0.0%) 1 (2.8%) 0.08
Number of previous 
symptomatic episodes
1 (1–5) 3 (2–10) < 0.05 6 (1–15) 2 (1–6) 0.07
Duration of longest 
previous episode* 
91.3  
(30.4–304.4)
76.1  
(60.9–243.5)
0.92 0.8  
(0.2–2.0)
1.0  
(0.3–2.0)
0.29
Duration of current 
episode of AF* 
51.0  
(2.0–159.0)
127.0  
(13.0–271.0)
0.32 0.0  
(0.0–1.0)
0.0  
(0.0–2.0)
0.11
Time since first  
episode of AF ever* 
773.5  
(222.5–3241.0)
1197.0  
(413.0–3661.0)
0.42 1399.0  
(299.5–3387.5)
950.5  
(121.0–4352.5)
0.97
Echocardiographic  
parameters
Size of left  
atrium [mm]
44.0 (41.0–47.0) 45.5 (43.0–47.5) 0.31 41.5 (37.0–45.0) 44.0 (40.0–46.0) 0.16
Left ventricular diastolic 
dimension [mm]
52.0 (48.0–56.0) 51.0 (47.0–58.0) 0.74 50.0 (45.0–53.0) 50.5 (47.0–54.0) 0.50
Left ventricular ejection 
fraction < 45%
26 (27.1%) 4 (33.3%) 0.65 6 (7.7%) 4 (18.2%) 0.15
Abbreviations — see Table 1
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syndrome in 6 (4.1%) patients, stable corona-
ry disease in 5 (3.4%) patients, heart failure in 
4 (2.7%) patients, and valvular heart disease in 
3 (2.1%) patients. The median time to initiation 
of cardioversion among those undergoing primary 
PCV was 2:14 h (IQR 0:30–17:50). Among these 
patients, the median time to reach SR was 180 min 
(IQR 72–740). A median of total length of hospital 
stay among patients with primary PCV was 70:38 h 
(IQR 17:50–99:03).
Clinical characteristics among the amiodaro-
ne, propafenone, beta-blockers (BB) and “other” 
groups were not statistically different (Table 3). 
AF as the primary reason for admission was the 
least frequent among patients in the amiodarone 
group; other AF characteristics were not signifi-
cantly different between the groups (Table 4). The 
dosage of the drugs and the route of administration 
are shown in Table 5. The most popular BB was 
metoprolol (88.2% of the patients treated only 
with BB and 87.8% of all the patients treated with 
BB). Nine (11.5%) patients treated initially with 
amiodarone were also treated with propafenone (all 
intravenously, a median dose of 140 mg). Primary 
PCV was successful in 110 (75.3%) patients. In 17 
(10.9%) patients, ECV was performed following 
unsuccessful PCV and all were successful (number 
of shocks 1.1 ± 0.3, first shock 129.1 ± 55.6 J). In 
2 (1.4%) patients, conversion from AF into atrial 
flutter or atrial tachycardia was observed. Diffe-
rences in successful conversion between groups 
were not statistically significant: from 69.4% in 
the propafenone group, to 80.0% in the other drug 
group (p = 0.90). The time to reach SR was the 
longest in the amiodarone group and the shortest 
in the BB group (p < 0.01), with the same trend 
in duration of hospital stay (p < 0.0001) (Table 6).
None of the echocardiographic or clinical pa-
rameters was different in patients with successful 
primary PCV in comparison with unsuccessful 
primary PCV. The only significant difference was in 
the number of the first detected episode (Table 2). 
All patients except for two were discharged from 
hospital. One hundred and six patients (96.3%) with 
the initial PCV successful and 19 (52.8%) patients 
(p < 0.0001) with the first PCV unsuccessful were 
in sinus/atrial paced rhythm upon discharge.
Complications and adverse events
During the hospital stay, 14 (2.8%) complica-
tions and adverse events were recorded. Among 
them, there was 1 transient ischemic attack, 1 pul- 
monary embolism, 2 exacerbations of heart failure, 
1 ventricular fibrillation, 1 syncope and 5 episodes 
of sinus syndrome insufficiency.
No stroke, major bleeding, torsade de pointes 
or hypotension were observed during the hospi-
talization.
Discussion
In the present manuscript, we document 
characteristics and current treatment patterns of 
patients who were admitted to the hospital to un-
Table 3. Clinical characteristics of the patients who underwent primary pharmacological cardioversion 
(PCV) depending on the drug.
Demographics  
and risk factors
Amiodarone  
or amiodarone  
and BB (n = 76)
Propafenone  
or propafenone  
and BB (n = 36)
BB as the  
only therapy  
(n = 17)
Other  
(n = 5)
P
Age 67.2 ± 12.7 67.3 ± 10.6 72.9 ± 11.0 61.4 ± 5.7 0.11
Women 42 (55.2%) 13 (36.1%) 11 (64.7%) 2 (40.0%) 0.15
Body mass index 28.1 ± 4.8 28.9 ± 3.6 29.2 ± 4.7 31.1 ± 2.9 0.23
Hypertension 63 (82.9%) 32 (88.9%) 15 (88.2%) 4 (80.0%) 0.82
Diabetes 15 (19.7) 12 (33.3%) 1 (5.9%) 1 (20%) 0.13
Hyperlipidemia 47 (65.3%) 19 (73.1%) 4 (40%) 4 (80%) 0.26
Coronary artery disease 22 (28.9%) 11 (30.6%) 2 (11.8%) 1 (20%) 0.47
Previous MI 11 (14.5%) 9 (25.0%) 0 (0%) 1 (20%) 0.13
Heart failure 12 (15.8%) 9 (25.0%) 0 (0%) 0 (0%) 0.09
Valvular heart disease 8 (11.0%) 3 (10.0%) 1 (6.3%) 0 (0%) 0.83
CHADS2 score 1.6 ± 1.1 1.7 ± 1.0 1.6 ± 0.9 1.0 ± 0.7 0.45
CHA2DS2-VASc score 3.0 ± 1.6 3.2 ± 1.6 3.1 ± 1.1 1.8 ± 1.6 0.43
BB — beta-blockers; MI — myocardial infarction
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Table 4. Atrial fibrillation (AF) characteristics of the patients who underwent primary pharmacological 
cardioversion (PCV) depending on the drug.
AF characteristics Amiodarone  
or amiodarone  
and BB (n = 76)
Propafenone  
or propafenone  
and BB (n = 36)
BB as the  
only therapy  
(n = 17)
Other  
(n = 5)
P
Primary reason for  
admission: AF
56 (73.7%) 33 (91.7%) 16 (94.1%) 5 (100%) < 0.05
First detected episode 
of AF
29 (38.2%) 7 (19.4%) 7 (41.2%) 0 (0.0%) 0.07
Paroxysmal AF 43 (56.6%) 27 (75.0%) 9 (52.9%) 5 (100%) 0.07
Persistent AF 3 (3.9%) 1 (2.8%) 1 (5.9%) 0 (0.0%) 0.92
Chronic AF 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.43
Number of previous 
symptomatic episodes
2.0 (1.0–10.0) 5.0 (2.0–15.0) 10.0 (1.0–20.0) 10 (5.0–60.0) 0.31
Duration of longest  
previous episode [days] 
0.8 (0.2–2.0) 0.3 (0.1–0.8) 1.0 (0.3–1.0) 2.0 (2.0–2.0) 0.17
Duration of current  
episode of AF [days] 
0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–0.0) 0.90
Time since first episode 
of AF ever [days] 
589.5  
(104.0–2134.0)
1901.0  
(866.0–4021.0)
674.0  
(64.0–1609.0)
1805.0 
(1422.0– 
–2188.0)
0.17 
BB — beta-blockers
Table 6. Results of primary pharmacological cardioversion (PCV). 
Details of PCV Total  
(n = 146)
Amiodarone or 
amiodarone and 
BB  
(n = 76)
Propafenone  
or propafenone 
and BB  
n = 36)
BB as the 
only therapy 
(n = 17)
Other  
(n = 5)
P 
Time to primary  
PCV* [h]
2:14  
(0:30–17:50)
1:40  
(0:20–9:50)
1:37  
(0:36–5:17)
1:40  
(1:24–4:36)
24:40  
(22:20–27:05)
< 0.05
Successful  
conversion
110 (75.3%) 57 (75.0%) 25 (69.4%) 13 (76.5%) 4 (80.0%) 0.90
Minutes to sinus  
rhythm*
180.0  
(72.0–740.0)
350.0  
(75.0–960.0)
230.0  
(120.0–840.0)
68.0  
(50.0–210.0)
75.0  
(30.0–110.0)
< 0.01
Duration of  
hospital stay* [h]
70:38  
(17:50–99:03)
84:15  
(70:14–145:26)
17:48  
(7:57–77:51)
7:09  
(3:08–41:43)
66:35  
(64:00–69:20
< 0.0001
*Median (interquartile range); BB — beta-blockers
Table 5. Registry drugs dosage and route of administration.
Drug Dose [mg]
Median (IQR)
Route of administration
Oral Intravenous
Amiodarone* 600 (300–900) 1 (1.3%) 77 (98.7%)
Propafenone* 300 (140–300) 28 (71.8%) 11 (28.2%)
Beta-blockers** Not applicable 8 (47.1%) 8 (47.1%)
Other Not applicable 0 (0%) 11 (100%)
*This include amiodarone + beta-blockers and propafenone + beta-blockers; **As the only therapy; IQR — interquartile range
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dergo cardioversion of AF. General characteristics 
of the whole group and comparison with other 
registries are described in another publication [5]. 
We show safety and effectiveness of cardioversion 
in a “real life” registry, with consecutive patients 
included, with wide inclusion criteria and very 
limited exclusions.
The RHYTHM-AF registry shows statistics of 
the hospitalized patients with AF who underwent 
rhythm control strategy. Out of all 501 patients 
in the Polish RHYTHM-AF registry, 207 (41.3%) 
did not undergo cardioversion, but this did not 
change rhythm control strategies. The most com-
mon reasons were planned cardioversion in the 
future and spontaneous SR restoration (68.2% for 
both reasons). Contraindications to cardioversion 
were found only in ~10% of all population; these 
included uncertain duration of current episodes of 
AF, left atrial thrombus or spontaneous echo con-
trast. Left atrial thrombus was found in 16 (3.2%) 
patients (in a large German cohort of over 3,000 
patients with AF who underwent TEE, the frequ-
ency of thrombus in the left atrium was comparable 
[6]). In 8 patients, the rhythm control strategy was 
changed into rate control (cardioversion was not 
attempted because of size of the left atrium).
The mode of cardioversion (primary PCV and 
primary ECV) was largely dependent on the type of 
AF. Among patients who underwent ECV, paroxy-
smal AF was less frequent and persistent AF was 
more common, duration of the longest previous 
episode and current episode were completely dif-
ferent. This is consistent with current guidelines 
and previous studies [1, 3].
Effectiveness of ECV in our registry was com-
parable to that reported in the literature (78–97%) 
[7–10]. Although some data suggest that in AF, 
200 J energy should be started, especially in non-
-paroxysmal AF [11], we show that about 160 J 
energy may also be effective.
Pharmacological cardioversion was performed 
almost exclusively in patients with paroxysmal or 
first detected episodes of AF. According to current 
guidelines [1], almost all amiodarone patients were 
treated intravenously, oral formulation of propafe-
none was more common (71.8%). In patients trea-
ted with propafenone and amiodarone, the addition 
of BB was considered a supplementary therapy, so 
patients treated with propafenone and propafenone 
with BB (or amiodarone and amiodarone in combi-
nation with BB) were analyzed together. Separate 
analyses were performed for patients treated with 
BB alone. Demographic characteristics of patients 
treated with amiodarone, propafenone and BB were 
not statistically different, although hyperlipidemia 
and coronary disease occurred less frequently 
among patients treated with BB, and none of these 
patients had a history of heart failure or myocardial 
infarction. Alternatively, although propafenone is 
contraindicated in patients with structural heart 
disease, 30% of patients treated with propafenone 
had a history of coronary disease, 25% a history of 
myocardial infarction and 25%, a history of heart 
failure. The other problem is propafenone dosing 
— although separate dosing for intravenous and 
oral applications is not available, we can conclude 
that oral doses given to the patients are lower than 
recommended in the guidelines [1]. Amiodarone 
dosing seems to be adequate. Of special interest is 
the successful conversion rate in the small (n = 17) 
group of patients treated with BB as the only 
therapy — 76.5%. Previous (although very old) 
experiences with metoprolol were not encouraging 
with only 13% rate of conversion [12]. Time to 
reach SR in patients treated with BB was also very 
short (median was 68 min), especially that almost 
half of the patients were treated orally. One might 
speculate that at least some of these episodes of AF 
would terminate spontaneously. Still, in relatively 
healthy populations with numerous previous epi-
sodes of AF that terminated spontaneously, adding 
a BB may be helpful in restoring SR.
The time to reach SR was the longest in pa-
tients treated with amiodarone and the shortest in 
patients treated with propafenone. This is consi-
stent with other observations — in a meta-analysis, 
efficacy of cardioversion of AF with amiodarone 
was inferior to class Ic drugs for up to 8 h but no 
difference was observed at 24 h [13]. There were 
statistically significant differences in hospitaliza-
tion time between patients treated with various 
pharmacological agents in PCV (with the longest 
duration being among patients in the amiodarone 
group), which may, in part, be due to the highest 
percentage of patients for whom AF was not 
a primary reason for admission into the amiodarone 
group, as well as the fact that amiodarone is known 
to have a far longer half-life, and takes a longer time 
to be effective [13].
We did not observe any clinical or echocar-
diographic parameters to vary significantly by 
the success of either primary PCV or ECV. Rate 
of complications was rather low, with single pa-
tients suffering serious complications including 
myocardial infarction, pulmonary embolism, 
or heart failure. A recent meta-analysis of AF 
cardioversion in emergency department shows 
comparable results [14].
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Limitations of the study
This is one of a few studies showing fate 
of patients with AF who are hospitalized with 
an intention to be cardioverted. Thanks to wide 
inclusion criteria, patients from the cohort are 
likely to reflect real life patients. This was a purely 
observational study, and so by design, has certain 
limitations on the types of conclusions which can 
be drawn. Treatment groups were not randomized, 
but rather reflect real-world treatments, where 
they are given at the physicians’ discretion, as were 
diagnostic tests and concomitant treatments, which 
were not made in a uniform fashion (for example 
echocardiography).
Conclusions
Less than 60% of the patients with AF admit-
ted to the hospital with the intention to terminate 
arrhythmia eventually underwent an attempt of 
conversion to SR. Primary ECV was chosen in 
51% of patients and was successful in ~90% of 
the patients. PVC was successful in ~75% of 
the patients. Amiodarone and propafenone were 
most commonly used with comparable efficacy. 
Rates of complications were low, with ~2.8% of 
patients experiencing adverse events during ho-
spitalization.
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